nach oben

Wiener Medizinische Wochenschrift

Erschienen in:

01.07.2012 | Kalzium in der kardialen Pathophysiologie

Arrhythmia-associated cardiac Ca²⁺ cycling proteins and gene mutations

verfasst von: Dr. Simon Kochhäuser, MD, Prof. Dr. Eric Schulze-Bahr, MD, Prof. Dr. Uwe Kirchhefer, MD

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 13-14/2012

Einloggen, um Zugang zu erhalten

Summary

Calcium is an important mediator in cardiac excitation and disorders in cardiac Ca²⁺ homeostasis have great influence on the cardiac action potential. Therefore dysfunction in regulatory proteins that are involved in Ca²⁺ handling can lead to the occurrence of severe arrhythmia. Although mutations in Ca²⁺ regulating proteins are quite rare, they can offer general insights into arrhythmogenesis. Here, we briefly review some important aspects of arrhythmia-associated mutations in Ca²⁺ regulating proteins with special emphasis to its associated pathophysiology.

Vorheriger Artikel Calcium handling and atrial fibrillation

Nächster Artikel Calcium handling in human heart failure—abnormalities and target for therapy

Bers DM. Cardiac excitation-contraction coupling. Nature. 2002;415:198–205.PubMedCrossRef

Hadri L, Hajjar RJ. Calcium cycling proteins and their association with heart failure. Clin Pharmacol Ther. 2011;90(4):620–4.PubMedCrossRef

Splawski I, Timothy KW, Decher N, Kumar P, Sachse FB, Beggs AH, et al. Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell. 2004;119:19–31.PubMedCrossRef

Antzelevitch C, Pollevick GD, Cordeiro JM, Casis O, Sanguinetti MC, Aizawa Y, et al. Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death. Circulation. 2007;15:442–9.CrossRef

Splawski I, Timothy KW, Decher N, Kumar P, Sachse FB, Beggs AH, et al. Severe arrhythmia disorder caused by cardiac L-type calcium channel mutations. Proc Natl Acad Sci U S A. 2005;102:8089–96.PubMedCrossRef

Splawski I, Timothy KW, Priori SG, Napolitano C, Bloise R. Timothy Syndrome. In: Pagon RA, Bird TD, Dolan CR, Stephens K, editors. Gene Reviews (Internet). Seattle: University of Washington, Seattle; 1993–2006 Feb 15 (updated 2011 Apr 21).

Antzelevitch C, Brugada P, Borggrefe M, Brugada J, Brugada R, Corrado D, et al. Brugada syndrome: report of the second consensus conference. Heart Rhythm. 2005;2(4):429–40.PubMedCrossRef

Wilde AA, Postema PG, Di Diego JM, Viskin S, Morita H, Fish JM, et al. The pathophysiological mechanism underlying Brugada syndrome: depolarization versus repolarization. J Mol Cell Cardiol. 2010;49(4):543–53.PubMedCrossRef

Marx SO, Reiken S, Hisamatsu Y, Jayaraman T, Burkhoff D, Rosemblit N, et al. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell. 2000;101:365–76.PubMedCrossRef

10.

Zhang L, Kelley J, Schmeisser G, Kobayashi YM, Jones LR. Complex formation between junctin, triadin, calsequestrin, and the ryanodine receptor. Proteins of the cardiac junctional sarcoplasmic reticulum membrane. J Biol Chem. 1997;272:23389–97.PubMedCrossRef

11.

Györke I, Hester N, Jones LR, Györke S. The role of calsequestrin, triadin, and junctin in conferring cardiac ryanodine receptor responsiveness to luminal calcium. Biophys J. 2004;86:2121–8.PubMedCrossRef

12.

Hasenfuss G, Pieske B. Calcium cycling in congestive heart failure. J Mol Cell Cardiol. 2002;34:951–69.PubMedCrossRef

13.

Priori SG, Napolitano C, Tiso N, Memmi M, Vignati G, Bloise R, et al. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation. 2001;103:196–200.PubMedCrossRef

14.

Lahat H, Pras E, Olender T, Avidan N, Ben-Asher E, Man O, et al. A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel. Am J Hum Genet. 2001;69:1378–84.PubMedCrossRef

15.

Kirchhefer U, Wehrmeister D, Postma AV, Pohlentz G, Mormann M, Kucerova D,et al. The human CASQ2 mutation K206N is associated with hyperglycosylation and altered cellular calcium handling. J Mol Cell Cardiol. 2010;49:95–105.PubMedCrossRef

16.

Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Heart Rhythm. 2011;8:1308–39.PubMedCrossRef

17.

Roux-Buisson N, Cacheux M, Fourest-Lieuvin A, Fauconnier J, Brocard J, Denjoy I, et al. Absence of triadin, a protein of the calcium release complex, is responsible for cardiac arrhythmia with sudden death in human. Hum Mol Genet. 2012;21(12):2759–67.

18.

George CH, Higgs GV, Lai FA. Ryanodine receptor mutations associated with stress-induced ventricular tachycardia mediate increased calcium release in stimulated cardiomyocytes. Circ Res. 2003;93:531–40.PubMedCrossRef

19.

Houle TD, Ram ML, Cala SE. Calsequestrin mutant D307H exhibits depressed binding to its protein targets and a depressed response to calcium. Cardiovasc Res. 2004;64:227–33.PubMedCrossRef

20.

Dirksen WP, Lacombe VA, Chi M, Kalyanasundaram A, Viatchenko-Karpinski S, Terentyev D, et al. A mutation in calsequestrin, CASQ2D307H, impairs Sarcoplasmic Reticulum Ca²⁺ handling and causes complex ventricular arrhythmias in mice. Cardiovasc Res. 2007;75:69–78.PubMedCrossRef

21.

Jiang D, Xiao B, Zhang L, Chen SR. Enhanced basal activity of a cardiac Ca²⁺ release channel (ryanodine receptor) mutant associated with ventricular tachycardia and sudden death. Circ Res. 2002;91:218–25.PubMedCrossRef

22.

Priori SG, Corr PB. Mechanisms underlying early and delayed afterdepolarizations induced by catecholamines. Am J Physiol. 1990;258:H1796–805.PubMed

23.

Postma AV, Denjoy I, Kamblock J, Alders M, Lupoglazoff JM, Vaksmann G, et al. Catecholaminergic polymorphic ventricular tachycardia: RYR2 mutations, bradycardia, and follow up of the patients. J Med Genet. 2005;42:863–70.PubMedCrossRef

24.

Priori SG, Napolitano C, Memmi M, Colombi B, Drago F, Gasparini M, et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation. 2002;106:69–74.PubMedCrossRef

25.

Priori SG, Napolitano C, Schwartz PJ, Grillo M, Bloise R, Ronchetti E, et al. Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. JAMA. 2004;292:1341–4.PubMedCrossRef

26.

Leenhardt A, Lucet V, Denjoy I, Grau F, Ngoc DD, Coumel P. Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients. Circulation. 1995;91:1512–9.PubMedCrossRef

27.

Swan H, Laitinen P, Kontula K, Toivonen L. Calcium channel antagonism reduces exercise-induced ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia patients with RyR2 mutations. J Cardiovasc Electrophysiol. 2005;16:162–6.PubMedCrossRef

28.

Sumitomo N, Harada K, Nagashima M, Yasuda T, Nakamura Y, Aragaki Y, et al. Catecholaminergic polymorphic ventricular tachycardia: electrocardiographic characteristics and optimal therapeutic strategies to prevent sudden death. Heart. 2003;89:66–70.PubMedCrossRef

29.

Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Circulation. 2006;114:e385–484.PubMedCrossRef

30.

Watanabe H, Chopra N, Laver D, Hwang HS, Davies SS, Roach DE, et al. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med. 2009;15:380–3.PubMedCrossRef

Titel: Arrhythmia-associated cardiac Ca2+ cycling proteins and gene mutations
verfasst von: Dr. Simon Kochhäuser, MD
Prof. Dr. Eric Schulze-Bahr, MD
Prof. Dr. Uwe Kirchhefer, MD
Publikationsdatum: 01.07.2012
Verlag: Springer Vienna
Erschienen in: Wiener Medizinische Wochenschrift / Ausgabe 13-14/2012
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI: https://doi.org/10.1007/s10354-012-0114-z

Springer Medizin Österreich

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 13-14/2012

Calcium handling in human heart failure—abnormalities and target for therapy

Calcium is omnipresent in the physiology and pathophysiology of heart disease

Calcium handling and atrial fibrillation

Pharmacology of myocardial calcium-handling

Odontogene Infektionen – Teil I

Calcium handling and ventricular tachyarrhythmias